This appointment continues Lavie Bio’s advancement of its commercial pipeline, focusing on its planned product launches starting 2022
Rehovot, Israel – May 25th, 2021 – Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced the appointment of Mr. Russ Putland as Vice President Commercial. Russ’s significant commercial experience includes more than 30 years of leadership within large multinational agriculture companies. In his last leadership role, he led a sales organization at DuPont crop protection, accountable for $175 million in sales annually.
Russ brings a broad understanding of the commercial value chain and his experience includes working directly with farmers, retailers, distribution channels and manufacturers. Russ will lead Lavie Bio’s commercial strategy and execution, focusing on establishing relationships and partnerships with strategic and channel partners, driving revenue from ag-biological bio-stimulant and bio-pesticide product lines. Russ will be based at Lavie Bio’s U.S. site in St. Louis.
“I am happy to join the Lavie-Bio’s team at this exciting point in time as we advance towards the commercialization of our products. I’ve followed Lavie Bio’s progress closely and look forward to leading our products commercialization and sales execution” commented, Russ Putland, VP Commercial.
Ido Dor, Lavie Bio’s CEO, added: “It is great to see how our technology platform translates into commercialization of microbiome based ag-biological products. I am excited to see our vision, of improving food quality, sustainability and agricultural productivity becoming real. I am very happy with the addition of Russ to the Lavie Bio management team. No doubt that his experience and leadership will be a great addition to the Lavie family and drive our exciting journey of taking Lavie Bio to its next phase – commercialization of our product pipeline.”
About Lavie Bio Ltd.:
Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, harnessing the power of big data and advanced informatics, for the discovery, optimization and development of bio-stimulant and bio-pesticide products. Corteva, Inc. holds approximately 28% in Lavie Bio. For more information, please visit www.lavie-bio.com.
Forward Looking Statements
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. For example, Lavie Bio is using forward-looking statements in this press release when it discusses the timelines and success of its expected product launches and commercialization of its products. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Lavie Bio may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Lavie Bio, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene’s reports filed with the applicable securities authorities. In addition, Lavie Bio relies, and expects to continue to rely, on third parties to conduct certain activities, such as its field-trials, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Lavie Bio may experience significant delays in the conduct of its activities. Lavie Bio disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Investor and Public Relations Contacts:
Investor Relations and Public Relations Manager
T: +1 646-653-7030
T: +1 646-653-7035